| Abstrakt: |
This study aimed to explore the amelioration of immune function and clinical symptoms in epilepsy patients following the implementation of topiramate therapy. We retrospectively analyzed 90 epilepsy patients treated at our institution from September 2020 to July 2022, segregating them into two groups: the observation group (n = 50, administered with a combination of carbamazepine and topiramate), and the control group (n = 40, treated with carbamazepine alone). The study evaluated disparities in clinical outcomes, immune function modifications, epilepsy score variances, quality of life indices, and incidence of adverse reactions before and after treatment in both groups. The observation group demonstrated a total treatment efficacy rate of 94.00% (47/50), significantly exceeding that of the control group, which stood at 75.00% (30/40) (P < 0.05). Pre-treatment epilepsy and QOLIE-31 scores showed no statistically meaningful difference between the two groups (P > 0.05); however, post-treatment evaluation after 3 months indicated that the observation group had significantly lower epilepsy scores and notably higher QOLIE-31 scores (P < 0.05). Although pre-treatment immune function indices (including CD3+, CD4+, and IgA levels) did not show a significant difference between the groups (P > 0.05), post-treatment levels of CD3+ and CD4+ were markedly higher, and IgA levels were lower in the observation group (P < 0.05). The observation group also exhibited a reduced overall incidence of adverse reactions (12.00%, 6/50), significantly lower than the control group (32.50%, 13/40) (P < 0.05). The adjunctive use of topiramate with standard therapy can enhance the clinical efficacy in epilepsy patients, ameliorating immune function, augmenting the quality of life, and escalating treatment safety, thereby presenting substantial value for clinical application. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink